Vimseltinib – CSF1R inhibitor
Chronic graft-versus-host disease (cGVHD)
About This Program
- Colony-stimulating factor 1 receptor (CSF1R) signaling is a key pathway involved in the expansion and infiltration of donor-derived macrophages that mediate chronic graft-versus-host disease (cGVHD).1,2
- cGVHD and its treatment typically require the prolonged use (2–3.5 years) of immunosuppressants.1,2
- Both cGVHD and its treatment are associated with high morbidity and late mortality, with 5-year and 12-year cumulative incidence estimates of nonrelapse mortality being 23% and 40%, respectively.1,2
- Vimseltinib is an oral, switch-control kinase inhibitor designed to selectively and potentially inhibit CSF1R.3
- Based on the manageable safety profile, vimseltinib is currently being investigated for treatment of cGVHD.
Deciphera is currently enrolling patients in a Phase 2 study of vimseltinib in adults with active cGVHD.
To learn more about this study, click here.
References
1Malard F, et al. Hematol. 2023;98(10):1637-1644.
2DeFilipp Z, et al. Blood Adv. 2021;5(20):4278-4284.
3Smith BD, et al. Mol Cancer Ther. 2021;20(11):2098-2109.